openPR Logo
Press release

Living with Schizophrenia: A Misunderstood and Stigmatized Illness

05-30-2011 08:22 AM CET | Leisure, Entertainment, Miscellaneous

Press release from: Living with Schizophrenia

Living with Schizophrenia: A Call for Hope and Recovery

Living with Schizophrenia: A Call for Hope and Recovery

San Diego, CA – May 27, 2011 - “Living with Schizophrenia: A Call for Hope and Recovery” is a half-hour documentary film that tells the story of three people who are living meaningful lives with schizophrenia, a chronic and potentially disabling brain disorder. Visit http://www.hopeandrecoveryfilm.com/videos/trailer.swf to view the documentary trailer. The film sets out to increase understanding and to reduce the fear and stigma often associated with this mental health condition. About one percent of the US adult population, or 2 million, and approximately 24 million people globally are living with schizophrenia.

“‘Living with Schizophrenia’ highlights the stories that don’t make the headlines – the stories of hope and promise,” said Emily Abt, award-winning filmmaker and director of the film. “My grandmother struggled with schizophrenia, and making this documentary gave me new insights about what it is like to have this illness and overcome the obstacles in life that it presents.”

In the film, viewers journey with three individuals with schizophrenia to experience their daily struggles, personal insights, paths to the mental health recovery process, and the impact their illness has had on those who love them. “Living with Schizophrenia” delves into the lives of Ashley, who after finding effective treatment for her schizophrenia, returned to school and created a blog to share her story with others; Joshua, who was in and out of psychiatric hospitals for six years and now, following his path of mental health recovery, is dedicated to helping others living with the illness; and Rebecca, who spent a decade blaming herself for her diagnosis of paranoid schizophrenia and is now actively involved in her treatment process.

Ashley, Joshua, and Rebecca are joined in the film by their families and experts in schizophrenia, including community-based psychiatrist Rebecca Roma, MD, medical director of the Community Treatment Team at Mercy Behavioral Health in Pittsburgh, Pennsylvania; Xavier Amador, PhD, clinical psychologist and founder and director of the LEAP Institute; and, Dave, president of the Georgia chapter of the National Alliance on Mental Illness (NAMI). Throughout the film, they share their perspectives and reinforce the message of hope and self-acceptance for people living with schizophrenia.

Schizophrenia is a complex mental disorder whose cause eludes experts to this day. Researchers have identified various risk factors for schizophrenia, including heredity, brain damage, and environmental factors such as social stress, isolation, and drug use. The disease typically manifests as abnormal psychological functioning and disturbed behavior. There are currently no physical or lab tests that diagnose the disease; therefore, schizophrenia is diagnosed by the presence of symptom types.

“By sharing the powerful stories of Ashley, Joshua, and Rebecca, we can work to reduce the fear and reduce the stigma, just like we’ve done with so many other issues over the years,” said Dr. Roma. “Deep down inside, we’re all people with different struggles and I learn from my patients every day about the power of perseverance and hope.”

“Living with Schizophrenia” was funded and produced by Janssen, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. The people featured in the film present their own stories and ideas and were not compensated by Janssen to appear in the film. Janssen products are not named or promoted in the film.

For more information about “Living with Schizophrenia” visit http://www.hopeandrecoveryfilm.com.

Boom Broadcast
4 Hill Spruce
Littleton, CO 80127

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Living with Schizophrenia: A Misunderstood and Stigmatized Illness here

News-ID: 177033 • Views:

More Releases for Schizophrenia:

Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts Schizophrenia Market Size Growth Forecast: What to Expect by 2025? In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased
Clozapine Market: Transforming the Treatment Landscape for Schizophrenia
Clozapine, an atypical antipsychotic medication, has emerged as a critical treatment option for patients with treatment-resistant schizophrenia and other severe psychiatric disorders. As one of the most effective therapies available for reducing symptoms in individuals who do not respond adequately to other antipsychotic medications, clozapine plays a vital role in modern psychiatry. This article provides a comprehensive overview of the clozapine market, exploring market information, key trends, challenges, and detailed
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026. Market Overview for Schizophrenia Drugs Market Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871 This latest report researches the industry structure, sales, revenue,
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could